Triomics Closes $22 Million Series B Led by Battery Ventures on May 28

According to TechCrunch, AI oncology platform Triomics closed a $22 million Series B round on May 28, led by Battery Ventures. Nexus Venture Partners, Lightspeed, and Y Combinator participated as existing investors.

Triomics develops an AI-driven platform to help oncologists and administrative staff automate clinical trial matching and appointment preparation. The company, founded in 2021, previously raised $15 million in Series A funding in mid-2024 and has since expanded its platform capabilities, including verifiable patient summary features integrated directly into existing clinical tools.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments